Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer
Laura R Moffitt, Nazanin Karimnia, Amy L Wilson, Andrew N Stephens, Gwo-Yaw Ho, Maree Bilandzic · 2024
Read Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer by Laura R Moffitt, Nazanin Karimnia, Amy L Wilson, Andrew N Stephens, Gwo-Yaw Ho, Maree Bilandzic (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11674382.txt.
Description
Laura Moffitt and five colleagues review why precision medicine has been slow to reach ovarian cancer care, in a paper from two thousand twenty-four. Targeted treatment changed the face of care for a range of cancers. Ovarian tumors are diverse and heterogeneous. They do not yield to the same playbook that worked for the rest.
The blocks start with tissue: to get adequate, representative samples is hard. The ways to screen lack standardization. They also lack proof that they work in the way they should. Data systems and the work of running them add friction at each step. Consent, privacy, and health equity raise the stakes on the ethics side. Costs make all of it still more hard to do. The team puts forth strategies that stress accessibility and education, for patients and professionals alike. Rules in this field should back the move of profiling into routine clinical care.
Catalog record
| CREATOR | Laura R Moffitt, Nazanin Karimnia, Amy L Wilson, Andrew N Stephens, Gwo-Yaw Ho, Maree Bilandzic |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |